197 related articles for article (PubMed ID: 35714823)
1. Ursolic acid enhances the antitumor effects of sorafenib associated with Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer.
Li H; Yu Y; Liu Y; Luo Z; Law BYK; Zheng Y; Huang X; Li W
Pharmacol Res; 2022 Aug; 182():106306. PubMed ID: 35714823
[TBL] [Abstract][Full Text] [Related]
2. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
Shi Z; Li Z; Jin B; Ye W; Wang L; Zhang S; Zheng J; Lin Z; Chen B; Liu F; Zhang B; Ding X; Yang Z; Shan Y; Yu Z; Wang Y; Chen J; Chen Q; Roberts LR; Chen G
Clin Transl Med; 2023 Jun; 13(6):e1300. PubMed ID: 37337470
[TBL] [Abstract][Full Text] [Related]
3. Suppression of the SLC7A11/glutathione axis causes ferroptosis and apoptosis and alters the mitogen-activated protein kinase pathway in nasopharyngeal carcinoma.
Wang HH; Fan SQ; Zhan YT; Peng SP; Wang WY
Int J Biol Macromol; 2024 Jan; 254(Pt 3):127976. PubMed ID: 37951442
[TBL] [Abstract][Full Text] [Related]
4. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C
J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718
[TBL] [Abstract][Full Text] [Related]
5. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma.
Huang CY; Chen LJ; Chen G; Chao TI; Wang CY
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232407
[TBL] [Abstract][Full Text] [Related]
6. Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer.
Yang J; Zhou Y; Xie S; Wang J; Li Z; Chen L; Mao M; Chen C; Huang A; Chen Y; Zhang X; Khan NUH; Wang L; Zhou J
J Exp Clin Cancer Res; 2021 Jun; 40(1):206. PubMed ID: 34162423
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines.
Zheng J; Sato M; Mishima E; Sato H; Proneth B; Conrad M
Cell Death Dis; 2021 Jul; 12(7):698. PubMed ID: 34257282
[TBL] [Abstract][Full Text] [Related]
8. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.
Huang W; Chen K; Lu Y; Zhang D; Cheng Y; Li L; Huang W; He G; Liao H; Cai L; Tang Y; Zhao L; Pan M
Neoplasia; 2021 Dec; 23(12):1227-1239. PubMed ID: 34768109
[TBL] [Abstract][Full Text] [Related]
9. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265
[TBL] [Abstract][Full Text] [Related]
10. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
Koppula P; Zhuang L; Gan B
Protein Cell; 2021 Aug; 12(8):599-620. PubMed ID: 33000412
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA CASC11 suppresses sorafenib-triggered ferroptosis via stabilizing SLC7A11 mRNA in hepatocellular carcinoma cells.
Chen F; Wang L
Discov Oncol; 2023 Aug; 14(1):145. PubMed ID: 37552314
[TBL] [Abstract][Full Text] [Related]
12. Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells.
Wang K; Zhang Z; Tsai HI; Liu Y; Gao J; Wang M; Song L; Cao X; Xu Z; Chen H; Gong A; Wang D; Cheng F; Zhu H
Cell Death Differ; 2021 Apr; 28(4):1222-1236. PubMed ID: 33097833
[TBL] [Abstract][Full Text] [Related]
13. ATF3 promotes ferroptosis in sorafenib-induced cardiotoxicity by suppressing Slc7a11 expression.
Li Y; Yan J; Zhao Q; Zhang Y; Zhang Y
Front Pharmacol; 2022; 13():904314. PubMed ID: 36210815
[TBL] [Abstract][Full Text] [Related]
14. Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy.
Li Q; Chen K; Zhang T; Jiang D; Chen L; Jiang J; Zhang C; Li S
Eur J Pharmacol; 2023 Sep; 955():175913. PubMed ID: 37460053
[TBL] [Abstract][Full Text] [Related]
15. MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferroptosis induction.
Huang CY; Chen LJ; Chen CS; Wang CY; Hong SY
Cell Death Discov; 2024 Mar; 10(1):137. PubMed ID: 38485916
[TBL] [Abstract][Full Text] [Related]
16. Amphiphilic Dendrimer Doping Enhanced pH-Sensitivity of Liposomal Vesicle for Effective Co-delivery toward Synergistic Ferroptosis-Apoptosis Therapy of Hepatocellular Carcinoma.
Su Y; Zhang Z; Lee LTO; Peng L; Lu L; He X; Zhang X
Adv Healthc Mater; 2023 Jan; 12(6):e2202663. PubMed ID: 36653312
[TBL] [Abstract][Full Text] [Related]
17. Artesunate synergistically promotes sorafenib‑induced apoptosis and ferroptosis in non‑Hodgkin lymphoma cells through inhibition of the STAT3 pathway.
Chen Y; Tao H; Wang F; Wu P; Gao J; Zhang X; He Z; Zhou Z; Jia Y
Oncol Rep; 2023 Jul; 50(1):. PubMed ID: 37326033
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Amplification of Ferroptosis with Liposomal Oxidation Catalyst and Gpx4 Inhibitor for Enhanced Cancer Therapy.
Yuan Y; Tian C; Wang Q; Qiu X; Wang Y; Jiang H; Hao J; He Y
Adv Healthc Mater; 2023 Nov; 12(28):e2301292. PubMed ID: 37458333
[TBL] [Abstract][Full Text] [Related]
19. Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism.
Cui Z; Wang H; Li S; Qin T; Shi H; Ma J; Li L; Yu G; Jiang T; Li C
J Pharmacol Sci; 2022 Jan; 148(1):73-85. PubMed ID: 34924133
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
